English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Recently, studies in the field of epidermal growth factor (EGF) +61A/G polymorphisms have shown their relevance in relation to cancer behavior. The role of EGF+61 genotypes has been determined in relation to several types of cancer, such as gliomas, gastric cancer and colorectal cancer (CRC). In 2011, it was demonstrated that these polymorphisms could also serve as predictive biomarkers for CRC patients treated with cetuximab.1 In relation to lung cancer, controversy continues to surround the results.2-4 Thus, the purpose of this letter is to provide a point of view and discuss relevant issues within this framework, focusing on a Portuguese study4 that contrasts with previous Asian studies2,3 published in the literature.

Back to EGF+61 genetic polymorphisms and lung cancer risk: looking to the future!